A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
NCT06695845
This study is recruiting at 5 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Breast Cancer
- Gastric Cancer
- Esophageal Cancer
- Gastroesophageal Cancer
- Colorectal Cancer
- Endometrial Cancer
- Non-small Cell Lung Cancer
- Ovarian Cancer
- Urothelial Carcinoma
- Salivary Gland Cancer
- Pancreatic Cancer
- HER-2 Protein Overexpression
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Jazz Pharmaceuticals
- Last updated on ClinicalTrials.gov
- July 10, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Colorado · 1
- Rocky Mountain Cancer Center · Littleton, CO
New York · 1
- Memorial Sloan Kettering Cancer Center · New York, NY
Tennessee · 1
- SCRI Oncology Partners · Nashville, TN
Texas · 2
- Texas Oncology - DFW · Dallas, TX
- MD Anderson Cancer Center · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.